Varatika Bhasma

Safety, contraindications and cautions

Compiled from published regulatory and institutional sources, listed against each statement. This is a reference summary, not advice about your own use. Ayurvedic preparations are dispensed by qualified practitioners, and anyone taking prescribed medication should raise an interaction with the prescriber rather than act on a page.

No published source describes this preparation specifically. No permitted source describes Varatika (Kapardika) Bhasma as a finished preparation in any way that supports a safety statement about it: no monograph, no elemental analysis, no clinical study, no case report naming it and no pharmacopoeial entry was located. SEARCHES, reported so they can be re-run. All were run against the NCBI E-utilities esearch endpoint on 2026-09-11 and each is quoted with the result it actually returned. db=pubmed, term 'Varatika': Count 0. db=pubmed, term 'Kapardika': Count 1, PMID 31000993, 'Comparative pharmacognostical analysis through quantitative micrometry and analytical study on Mridu and Tikshna Apamarga Kshara' (Ayu 2018), which concerns Apamarga Kshara and not this preparation. db=pubmed, term '"Kapardika bhasma"': Count 0, returned with WarningList QuotedPhraseNotFound and QueryTranslation '"kapardika"[All Fields] AND ("bhasma"[All Fields] OR "bhasmas"[All Fields])'. db=pubmed, term '"Varatika bhasma"': Count 222, but PubMed likewise returns WarningList QuotedPhraseNotFound for that phrase and rewrites the query to QueryTranslation '"bhasma"[All Fields] OR "bhasmas"[All Fields]', so the 222 records are the general bhasma literature and not hits on this preparation; no claim is made here about their contents. db=pubmed, term '"Cypraea moneta"': Count 1, PMID 28480388, Togun et al., a study of the RAW cowry shell and its extracted proteins, not of the calcined preparation; it is cited in this record as source v9. db=pmc, term '"Varatika bhasma"': Count 3 (PMC9757503, PMC4147483, PMC3960793). db=pmc, term 'Varatika': Count 4 (the same three plus PMC3336693). db=pmc, term '"Kapardika bhasma"': Count 9 (PMC12447158, PMC12148575, PMC12008519, PMC11802355, PMC11530780, PMC9988554, PMC8185977, PMC7685255, PMC3087364). WHAT THOSE HITS CONTAIN. PMC3960793 (Pal et al.) is a descriptive and pharmacognostic bhasma review; it identifies the source material and gives a partial constituent list, and performs no toxicological assay and no assay for lead, mercury, arsenic or cadmium. PMC4147483 (Bhatt) is a one-page conference abstract of an aspirin-induced gastric-lesion model in rats; it states that the bhasma 'was analyzed and used for experimental study' but reports no analytical, toxicological, biochemical, haematological or adverse-event result of any kind. PMC9757503 is the AYUSH Cancer Conclave 2019 accepted-abstract collection, in which Varatika Bhasma appears only inside a proposed multi-drug treatment protocol with no safety, dose or analytical data. PMC3336693 is a 1982 'Research in progress' note in Ancient Science of Life whose PMC record carries no extractable full text (the article page states 'The Full Text of this article is available as a PDF (12.5 KB)' and the HTML page has no body text), so no content could be extracted from it. PMC7685255 (Panigrahi et al.) is the only repeated-dose toxicology study located that contains this ingredient, and it tested it inside a nine-ingredient capsule that also contains purified aconite (Aconitum ferox), so its findings can be attributed to Varatika Bhasma neither as harm nor as reassurance; it was also financially supported by the manufacturer of the test article. The remaining PMC hits (PMC12447158, PMC12148575, PMC12008519, PMC11802355, PMC11530780, PMC9988554, PMC8185977, PMC3087364) were opened and are multi-ingredient clinical case reports, a proprietary-tablet animal study, a systematic review and a mica-bhasma characterisation paper; none reports a single-ingredient finding for this preparation. Targeted searches were also run against the permitted regulatory and consumer-information hosts (who.int, ayush.gov.in, pharmacopoeia.gov.in, ema.europa.eu, fda.gov, nccih.nih.gov, ods.od.nih.gov, mskcc.org, medlineplus.gov) and returned no entry for Varatika Bhasma, Kapardika Bhasma or Cypraea moneta. CONSEQUENCES. No entry-specific adverse-event, interaction, contraindication, pregnancy, lactation or elemental (lead, mercury, arsenic) data exist in the permitted sources. No dose field is carried. The only numeral located in a single-ingredient publication appears in Bhatt's abstract inside a comparison line, '(Sucralfate 1 gm 6 hourly and Varatika Bhasma 250 mg twice daily)', alongside what is a human sucralfate regimen; the abstract never states whose dose either numeral is, states no route and states no per-kilogram basis, so the figure is withheld rather than reproduced. No efficacy, indication or comparator information is carried anywhere in this record. Because insufficientData is true, every statement below is scoped class-level. That includes source v9: Togun et al. studied protein extracted from raw, sun-dried, pulverised Cypraea moneta shell given by intraperitoneal injection to mice, which is the source material of this preparation and not the shodhana-processed, calcined article, so it supports no preparation-specific statement either.

Everything below concerns the wider class this preparation belongs to, not this preparation itself. It is included because the class-level evidence is substantial and directly relevant, and because leaving the section blank would imply an absence of risk that the literature does not support.

Heavy metal content

Identity, from the one source located that names this preparation: Pal et al. state that 'Varatika is identified as the external shell of sea animal Cypraea moneta Linn.', that 'Cypraea moneta is commonly known as the money cowry', and that 'Chemically it is carbonate of calcium.' They describe the ingredients as 'the raw Varatika, Kulattha kashaya (Horse gram decoction for purification), Kumari svarasa (Aloe-vera juice) for grinding during incineration', the organoleptic properties as 'color is dull white fine powder, odorless, tasteless soluble in dilute HCl', and the physico-chemical analysis as 'Loss on drying (0.6566%). It contains ash (2.06%), organic carbon (1.09%), total nitrogen (0.72%), total potassium (3.49%), total zinc (1.48 ppm), total iron (113.6 ppm).' That constituent list did NOT test for lead, mercury, arsenic or cadmium. It is therefore not evidence that those metals are absent and must not be read as a clean elemental assay. No published elemental assay of Varatika Bhasma for lead, mercury or arsenic was located in any permitted source. This is a shell-derived calcium-carbonate preparation rather than a lead-, mercury- or arsenic-based bhasma, but class-level marketplace findings still apply to any bhasma bought as a finished product. Saper et al. requested 230 Ayurvedic medicines sold via the internet and received and analysed 193: 'The prevalence of metal-containing products was 20.7% (95% confidence interval [CI], 15.2%-27.1%).' 'Rasa shastra compared with non-rasa shastra medicines had a greater prevalence of metals (40.6% vs 17.1%; P=.007) and higher median concentrations of lead (11.5 microgram/g vs 7.0 microgram/g; P=.03) and mercury (20 800 microgram/g vs 34.5 microgram/g; P=.04).' Those medians carry the paper's own denominator note, reproduced here because it changes what they mean: 'The median metal concentration presented is for medicines with detectable amounts of the respective metal.' 'All metal-containing products exceeded 1 or more standards for acceptable daily intake of toxic metals.' Their stated limitations are carried with the finding: 'Limitations of our study include potential misclassification of the product's country of manufacture and rasa shastra status'; 'We did not assess batch-to-batch variability in metal concentrations'; and 'Wide variation among published standards for acceptable limits of daily metal ingestion makes it difficult to assess the magnitude of potential toxicity for different products.' Bhalla and Pannu sampled over-the-counter Ayurvedic preparations from licensed shops in Chandigarh in 2017; the denominator is their own: 'Out of 43 Ayurvedic preparations, 42 were analyzed. Heavy metals were detected in all formulations.' Of those 42 analysed formulations, 'The metal contents above the FAO/WHO-mandated limit for zinc, mercury, arsenic, and lead were detected in 35, 29, 6, and 2 formulations, respectively.' Median (range) concentrations in microgram/g were mercury 13.52 (0.00-61 095.99), arsenic 0.00 (0.00-1038.83), lead 1.40 (0.00-57.09) and zinc 84.2200 (26.48-22 519.03). Their negative findings are carried alongside their positive ones: 'Cadmium was not found in any sample.' Only '27.9% (n = 12) Ayurvedic formulations had listed heavy metals on the label', so the absence of a metal declaration on a label is not evidence of the absence of the metal. Their stated limitations are also carried: 'a single-center observation limits the generalizability of the results' and 'Our study did not address the potential sources of increased toxic heavy metal contents.' Separately, and as a class-level consequence of calcination rather than a measurement of Varatika Bhasma, Pal et al. report that 'Bhasmas were analyzed and found to contain PAH (2.32-9.55 ppm) among the preparation tested. The benzo[a] pyrene level also varied, the highest concentration being 9.7 ppm.' FDA states, verbatim, that 'FDA warns consumers that using unapproved ayurvedic products containing harmful levels of heavy metals may cause heavy metal poisoning' and that 'Adults and children can become very sick when heavy metals accumulate in their bodies over time.'Pal D, Sahu CK, Haldar A. Bhasma: The ancient Indian nanomedicine. J Adv Pharm Technol Res. 2014;5(1):4-12. Descriptive and pharmacognostic review; identity and physico-chemical description only, no assay for lead, mercury, arsenic or cadmium.Saper RB, Phillips RS, Sehgal A, et al. Lead, Mercury, and Arsenic in US- and Indian-Manufactured Ayurvedic Medicines Sold via the Internet. JAMA. 2008;300(8):915-923.Bhalla A, Pannu AK. Are Ayurvedic medications store house of heavy metals? Toxicol Res (Camb). 2022;11(1):179-183.FDA warns about heavy metal poisoning associated with certain unapproved ayurvedic drug products.

Contraindications

• Do not useclass-level Pregnancy — Avoid. No pregnancy data exist for this preparation. The class-level evidence carried in this record documents lead and mercury exposure from marketed Ayurvedic preparations: Saper et al. found metals in 40.6% of rasa shastra products with median mercury of 20 800 microgram/g among products with detectable mercury, and 'All metal-containing products exceeded 1 or more standards for acceptable daily intake of toxic metals'; Bhalla and Pannu detected heavy metals in all 42 formulations analysed, with only 27.9% (n = 12) declaring any metal on the label; NCCIH reports that 'A 2015 published survey of people who use Ayurvedic preparations showed that 40 percent had elevated blood levels of lead and some had elevated blood levels of mercury.' WHO states that 'There is no level of exposure to lead that is known to be without harmful effects' and that 'Lead stored in bone may be released into the blood during pregnancy and expose the fetus.' Lead and mercury are developmental neurotoxicants, so the grading is avoid rather than caution. No reproductive or developmental endpoint was tested in any source cited here.Saper RB, Phillips RS, Sehgal A, et al. Lead, Mercury, and Arsenic in US- and Indian-Manufactured Ayurvedic Medicines Sold via the Internet. JAMA. 2008;300(8):915-923.Bhalla A, Pannu AK. Are Ayurvedic medications store house of heavy metals? Toxicol Res (Camb). 2022;11(1):179-183.NCCIH. Ayurvedic Medicine: In Depth.WHO. Lead poisoning and health (fact sheet).
• Do not useclass-level Breastfeeding — Avoid. No lactation data exist for this preparation. FDA states that 'If a mother has heavy metals in her body, the metals may enter her breast milk and be passed onto the baby during breastfeeding.' The same class-level lead and mercury exposure evidence applies as for pregnancy, and the exposed party is an infant, so the grading is avoid rather than caution.Bhalla A, Pannu AK. Are Ayurvedic medications store house of heavy metals? Toxicol Res (Camb). 2022;11(1):179-183.FDA warns about heavy metal poisoning associated with certain unapproved ayurvedic drug products.WHO. Lead poisoning and health (fact sheet).
• Do not useclass-level Infants, children and adolescents — Avoid. No paediatric data exist for this preparation. FDA states that 'Adults and children can become very sick when heavy metals accumulate in their bodies over time', and WHO states that 'Young children are particularly vulnerable to the toxic effects of lead and can suffer permanent adverse health impacts' and that there is no level of lead exposure known to be without harmful effects. Class-level marketplace contamination is documented in this record and label declaration is unreliable (27.9%, n = 12, of Bhalla and Pannu's formulations declared any metal).Bhalla A, Pannu AK. Are Ayurvedic medications store house of heavy metals? Toxicol Res (Camb). 2022;11(1):179-183.FDA warns about heavy metal poisoning associated with certain unapproved ayurvedic drug products.WHO. Lead poisoning and health (fact sheet).
• Majorclass-level Existing liver disease, hepatic impairment, or concurrent hepatotoxic drugs — Two independent class-level sources document hepatic injury, neither of them a study of this preparation. FIRST, Panigrahi et al.'s 28-day rat study of the nine-ingredient aconite-containing Bacnil capsule reports 'fatty degenerative changes, cell infiltration and sinusoidal inflammation in the liver' at TED x 10 and 'fatty changes in liver' at TED x 5, that in the recovery group 'fatty changes and sinusoidal inflammation in the liver of rats were observed', and in its Results that 'The changes were reversed in all organs in recovery study except liver after discontinuation of drug'. The paper's own Conclusion contradicts that, stating the liver changes were 'reverted in recovery study after discontinuation of drug'; both statements are carried. The authors state verbatim that the drug 'has the potential to damage the liver at a higher dose level on longer administration', while the triglyceride, VLDL-cholesterol and alkaline phosphatase increases underlying that inference carry no significance marker in Table 4 and are called non-significant by the authors themselves. That study was funded by the manufacturer of the test article, Zoetic Ayurvedic Pvt. Ltd. These are findings for a nine-ingredient aconite-containing capsule and CANNOT be assigned to Varatika Bhasma. SECOND, Togun et al. report 'a dose dependent hepatotoxicity effect in mice' from fibrous protein extracted from the raw Cypraea moneta shell given intraperitoneally, with no appreciable change at 10 mg/kg body weight and hepatocyte vacuolation, degenerative ballooning, distorted sinusoids and bile-canalicular dilatation at higher doses; that is raw source material by the injected route, not the calcined preparation by the oral route, and equally cannot be assigned to Varatika Bhasma. No permitted source states a liver-function monitoring protocol for this preparation, and none is invented here; the hazard is recorded so that it is not lost.Panigrahi B, Sharma S, Sitapara B, De S, Nariya M. Safety profile of Ayurvedic poly-herbomineral formulation - Bacnil capsule in albino rats. Ayu. 2019;40(3):185-191. Nine-ingredient aconite-containing formulation; not a single-ingredient study of Varatika Bhasma. Financially supported by Zoetic Ayurvedic Pvt. Ltd., the manufacturer of the test article; authors declare no conflicts of interest.Togun RA, Balogun RO, Adeyemi DO, et al. Isolation, characterization and immunochemical studies on fibrous proteins from cowry shell (Cypraea moneta, Linnaeus). Afr J Tradit Complement Altern Med. 2016;14(1):110-122. Study of RAW, uncalcined cowry shell and its extracted protein fractions, administered intraperitoneally to mice; not a study of Varatika Bhasma and not the oral route.
• Majorclass-level Renal impairment or existing kidney disease — Both class-level animal sources in this record report renal histopathology, and neither studied this preparation. Panigrahi et al. report 'mild fatty changes in kidney' at TED x 10 in the 28-day rat study of the nine-ingredient aconite-containing capsule, with no change at TED and with the change reverting in the recovery group; the same study found no significant change in relative kidney weight at any dose level and no significant change in blood urea or creatinine. Togun et al. report 'a dose-dependent renal damage marked by necrosis and fatty accumulations in the glomerulus of the kidney of mice treated with higher doses of CSP (>100 mg/kg body weight)' after intraperitoneal injection of protein extracted from the raw cowry shell. Neither finding can be assigned to Varatika Bhasma, and the second is neither the calcined article nor the oral route. The hazard is recorded rather than dropped; no monitoring protocol is stated by either source and none is invented here.Panigrahi B, Sharma S, Sitapara B, De S, Nariya M. Safety profile of Ayurvedic poly-herbomineral formulation - Bacnil capsule in albino rats. Ayu. 2019;40(3):185-191. Nine-ingredient aconite-containing formulation; not a single-ingredient study of Varatika Bhasma. Financially supported by Zoetic Ayurvedic Pvt. Ltd., the manufacturer of the test article; authors declare no conflicts of interest.Togun RA, Balogun RO, Adeyemi DO, et al. Isolation, characterization and immunochemical studies on fibrous proteins from cowry shell (Cypraea moneta, Linnaeus). Afr J Tradit Complement Altern Med. 2016;14(1):110-122. Study of RAW, uncalcined cowry shell and its extracted protein fractions, administered intraperitoneally to mice; not a study of Varatika Bhasma and not the oral route.
• Majorclass-level Gastric or duodenal mucosal disease, active gastrointestinal bleeding, or concurrent NSAID use — Panigrahi et al. report 'mild epithelial erosion in the stomach' at TED x 10 and 'epithelial erosion in the stomach' at TED x 5 in the 28-day rat study, reverting in the recovery group, and 'cell infiltration in the ileum' at TED x 10. Again these are formulation findings for a nine-ingredient aconite-containing capsule, funded by the manufacturer of that capsule, and cannot be assigned to Varatika Bhasma, but they are the only gastric and intestinal mucosal observations in the located literature and they are adverse ones. No gastroprotective claim of any kind is made or implied in this record.Panigrahi B, Sharma S, Sitapara B, De S, Nariya M. Safety profile of Ayurvedic poly-herbomineral formulation - Bacnil capsule in albino rats. Ayu. 2019;40(3):185-191. Nine-ingredient aconite-containing formulation; not a single-ingredient study of Varatika Bhasma. Financially supported by Zoetic Ayurvedic Pvt. Ltd., the manufacturer of the test article; authors declare no conflicts of interest.
• Do not useclass-level Animal-derived material: vegan, Jain, vegetarian, shellfish-free or other diets and observances excluding animal or marine-animal material — Disclosure and consent issue. This preparation is the calcined external shell of the marine gastropod Cypraea moneta Linn.; Pal et al. also note that 'Animal derivatives such as horns, shells, feathers, metallic and nonmetallic minerals are normally administered as Bhasma.' Anyone excluding animal or marine-animal material on dietary, religious or ethical grounds should be told the source material before use, and the hazard is carried through to this statement rather than raised and dropped.Pal D, Sahu CK, Haldar A. Bhasma: The ancient Indian nanomedicine. J Adv Pharm Technol Res. 2014;5(1):4-12. Descriptive and pharmacognostic review; identity and physico-chemical description only, no assay for lead, mercury, arsenic or cadmium.
• Majorclass-level Mollusc or shellfish allergy: the raw source material is documented to contain immunogenic protein, and the calcined preparation has never been tested — This entry is upgraded from an unknown to a documented source-material hazard. Togun et al. report that raw powdered Cypraea moneta shell contains 1.91% crude protein by dry weight, that fibrous protein extracted from it in citrate buffer resolves into two species (CSP1 91 kDa, CSP2 33 kDa), and that these 'formed clear precipitin lines on reaction with the corresponding antiserum in Ouchterlony plates, and also formed clear precipitin lines in immunoelecrophoresis experiments', from which they conclude 'that the fibrous proteins were immunogenic'. Their globular (PBS-extracted) fraction, by contrast, 'did not show any evidence of immune activation or toxicity'. That work was done on raw, sun-dried, pulverised shell, not on the shodhana-processed, calcined bhasma, and the authors give no evidence as to whether calcination destroys the proteins; their own recommendation is that future work 'should include methods for removing or deactivating the protein components'. No permitted source reports testing of any marketed batch of Varatika Bhasma for residual mollusc protein, and no allergenicity or hypersensitivity testing of the preparation exists. It can therefore be stated neither that calcination removes mollusc allergen nor that it does not, but the starting material is now known to carry immunogenic protein, so the residual risk for anyone with a known mollusc or shellfish allergy is an open one and is recorded as a hazard rather than as reassurance.Pal D, Sahu CK, Haldar A. Bhasma: The ancient Indian nanomedicine. J Adv Pharm Technol Res. 2014;5(1):4-12. Descriptive and pharmacognostic review; identity and physico-chemical description only, no assay for lead, mercury, arsenic or cadmium.Togun RA, Balogun RO, Adeyemi DO, et al. Isolation, characterization and immunochemical studies on fibrous proteins from cowry shell (Cypraea moneta, Linnaeus). Afr J Tradit Complement Altern Med. 2016;14(1):110-122. Study of RAW, uncalcined cowry shell and its extracted protein fractions, administered intraperitoneally to mice; not a study of Varatika Bhasma and not the oral route.
• Majorclass-level Any product supplied without a batch-specific heavy-metal certificate of analysis — No elemental assay of Varatika Bhasma for lead, mercury or arsenic exists in the permitted sources, and the class-level marketplace data show contamination that labels do not disclose: Bhalla and Pannu detected heavy metals in all 42 formulations analysed while only 27.9% (n = 12) listed any metal on the label, and Saper et al. found that all metal-containing products exceeded one or more acceptable-daily-intake standards, while noting their own limitation that 'We did not assess batch-to-batch variability in metal concentrations.' FDA warns that 'using unapproved ayurvedic products containing harmful levels of heavy metals may cause heavy metal poisoning.'Saper RB, Phillips RS, Sehgal A, et al. Lead, Mercury, and Arsenic in US- and Indian-Manufactured Ayurvedic Medicines Sold via the Internet. JAMA. 2008;300(8):915-923.Bhalla A, Pannu AK. Are Ayurvedic medications store house of heavy metals? Toxicol Res (Camb). 2022;11(1):179-183.FDA warns about heavy metal poisoning associated with certain unapproved ayurvedic drug products.

Reported adverse effects

• Acute single oral dose of a nine-ingredient formulation containing Kapardika (cowrie-shell) Bhasma: no toxicity or mortality observed in rats (single dose, 2000 mg/kg, female rats only, 14-day observation; no deaths and no signs recorded) — SEPARATE STUDY ARM, NOT PART OF THE 28-DAY REPEATED-DOSE STUDY. Panigrahi et al. conducted an acute oral toxicity study of the Bacnil capsule under OECD 425 using the limit dose test of the up-and-down procedure, in female Charles Foster albino rats only, fasted overnight, administered 2000 mg/kg in a sequential manner as a single dose, with observation for the first 4 h and up to 8 h on day 1 and thereafter every 24 h up to 14 days. The authors report: 'Bacnil at the oral dose of 2000 mg/kg did not produce any toxicity or mortality in albino rats', and conclude that the 'LD 50 value may be higher than 2000 mg/kg by oral route in rat and hence it can be categorized as substances with low health hazard potential.' FUNDING DISCLOSURE, carried adjacent to that exculpatory conclusion: the paper states 'This study was financially supported by Zoetic Ayurvedic Pvt. Ltd., Ahmedabad (Gujarat) and Institute for Post Graduate Teaching and Research in Ayurveda, Jamnagar' and thanks 'Zoetic Ayurvedic Pvt. Ltd., Ahmedabad (Gujarat), for funding and supporting the work'; Zoetic is the manufacturer that supplied the test article. The authors declare 'There are no conflicts of interest.' This is an acute, single-dose result in one sex and says nothing about repeated administration. It is also a result for the whole nine-ingredient capsule, which contains purified aconite (Aconitum ferox), and cannot be attributed to the cowrie-shell ingredient in either direction.Panigrahi B, Sharma S, Sitapara B, De S, Nariya M. Safety profile of Ayurvedic poly-herbomineral formulation - Bacnil capsule in albino rats. Ayu. 2019;40(3):185-191. Nine-ingredient aconite-containing formulation; not a single-ingredient study of Varatika Bhasma. Financially supported by Zoetic Ayurvedic Pvt. Ltd., the manufacturer of the test article; authors declare no conflicts of interest.
• Dose-related liver, stomach, heart, kidney and ileal histopathology, organ-weight changes, serum-biochemistry changes and haematology changes in a 28-day repeated-dose rat study of a nine-ingredient formulation containing Kapardika (cowrie-shell) Bhasma; the authors infer a potential for liver damage at higher dose on longer administration (no histopathological findings at TED; liver and stomach findings at 5x TED; findings in five organs at 10x TED; the authors' narrative text additionally asserts a significant uterus-weight increase and significant triglyceride and VLDL-cholesterol decreases at TED, but their own Tables 3 and 4 place no significance marker on any of those three rows and their own next paragraph calls the organ-weight changes non-significant, so those three are reported here as unresolved internal contradictions rather than as findings) — TEST ARTICLE, FUNDING AND LIMITS. Panigrahi et al. tested Bacnil capsule (Zoetic Ayurvedic Pvt. Ltd., Ahmedabad, batch no. 531681057, manufacturing date Dec 2015). The study was funded by that manufacturer: 'This study was financially supported by Zoetic Ayurvedic Pvt. Ltd., Ahmedabad (Gujarat) and Institute for Post Graduate Teaching and Research in Ayurveda, Jamnagar', and the acknowledgement thanks 'Zoetic Ayurvedic Pvt. Ltd., Ahmedabad (Gujarat), for funding and supporting the work'; the authors declare 'There are no conflicts of interest.' That sponsorship is recorded here because it bears directly on how the study's exculpatory conclusions, quoted below, should be read. Table 1, headed 'Composition of bacnil capsule in each 250 mg', lists: Vatsanabha, purified Aconitum ferox, 12.50 mg; Tankana 12.50 mg; Maricha 30.00 mg; Kapardika Bhasma (calcined cowries) 50.00 mg; Shankha Bhasma 25.00 mg; Muktashukti Bhasma 25.00 mg; Pathyadi Kwatha Ghana 70.00 mg, made up of seven herbs at 10.00 mg each (Terminalia chebula, Terminalia bellirica, Emblica officinalis, Tinospora cordifolia, Azadirachta indica, Andrographis paniculata, Curcuma longa); Kuberaksha 50.00 mg; Gairika 25.00 mg. These listed weights sum to 300 mg against the table's own stated 250 mg capsule, and the dose-selection paragraph states 'The human clinical dose of bacnil capsule (545 mg) is four capsules/day equal to 2180.0 mg/day.' Because the source is internally inconsistent on capsule weight, NO percentage share of the capsule is derived here for Kapardika Bhasma; only the stated 50.00 mg figure is reported. Because purified aconite is present, nothing in this study can be attributed to the cowrie-shell ingredient, as harm or as reassurance. DESIGN. Charles Foster albino rats of either sex, 200 +/- 20 g, randomly divided into five groups of 10 animals (5 male, 5 female). Group I control, distilled water 10 ml/kg orally; Group II therapeutic equivalent dose (TED) 196.2 mg/kg orally; Group III TED x 5, 981.0 mg/kg orally; Group IV TED x 10, 1962.0 mg/kg orally; all once daily for 28 consecutive days. Group V was an additional recovery group that received TED x 10 (1962.0 mg/kg orally) and was THE ONLY GROUP GIVEN A DRUG-FREE RECOVERY PERIOD, fixed in the Methods at 14 days after the 28-day main study (the abstract inconsistently states a 15-day recovery period). Statistics, as stated: mean +/- SEM, paired t-test and one-way ANOVA followed by Dunnett multiple t-test, significance at P < 0.05; in Tables 3, 4 and 5 the significance marker against control is '@'. DOSE-EXTRAPOLATION BASIS, stated by the authors: the human clinical dose of 2180.0 mg/day was extrapolated to rat 'based on body surface area ratio (conversion factor 0.018 for 200 g rat) by referring to the table of Paget and Barnes (1964)'. HISTOPATHOLOGY, verbatim: 'The results of histopathological studies suggest that bacnil at TED x 10 dose level produced fatty changes in the heart; fatty degenerative changes, cell infiltration and sinusoidal inflammation in the liver; cell infiltration in the ileum, mild fatty changes in kidney and mild epithelial erosion in the stomach. In the recovery study, fatty changes and sinusoidal inflammation in the liver of rats were observed. bacnil TED x 5 produced fatty changes in liver and epithelial erosion in the stomach while it was reverted in recovery study. No other changes were observed in any organs in Bacnil at TED-treated rats and in the control group.' The Results section adds: 'The changes were reversed in all organs in recovery study except liver after discontinuation of drug', i.e. the liver lesions were still present at the end of the 14 drug-free days while the other organ findings had reverted, and the legend to Figure 2 agrees, describing 'fatty changes and sinusoidal inflammation in TED x 10(r) rats'. A THIRD INTERNAL CONTRADICTION IS DISCLOSED HERE RATHER THAN RESOLVED: the paper's own Conclusion states the opposite of its Results on this point, saying the drug 'produced mild changes at TED x 10 dose level in the liver and kidney but same was reverted in recovery study after discontinuation of drug'. Both are reported; neither is suppressed. ORGAN WEIGHTS AND THE CONTRADICTION AROUND THEM. The narrative sentence reads, verbatim: 'Significant increase in the relative weight of seminal vesicle and (TED x 5) uterus (TED) and decrease in liver weight at TED x 5 dose level was observed in comparison to the control group.' Table 3 does not support all of that sentence. The only '@' markers in Table 3 fall on seminal vesicles at TED x 5 (704.37 +/- 18.21 @) and on liver at TED x 10 recovery (2.919 +/- 34.95 @). The uterus row carries no marker in any column (control 230.70 +/- 42.29; TED 346.50 +/- 20.78; TED x 5 319.67 +/- 28.89; TED x 10 300.78 +/- 26.33; TED x 10 recovery 300.12 +/- 43.81), and liver at TED x 5 carries no marker (3.004 +/- 0.07 against control 3.319 +/- 0.12). The paper then contradicts its own narrative two sentences later, and that passage is carried verbatim here because omitting it would be selective quotation: 'However, there were no significant changes in the relative weight of organs, namely kidney, heart, spleen, prostate and testis at all dose levels in comparison to the control group... The observed changes were devoid of any major adverse changes and were non-significant in comparison to the control group and it reversed in recovery duration; hence, it may be suggested that drugs do not seem to produce any toxic effect on the relative weight of important internal organ in repeated dose toxicity studies.' SERUM BIOCHEMISTRY, verbatim and with the authors' own significance qualifiers and their own hepatic inference retained in full: 'Data of serum biochemical parameters revealed that bacnil at TED dose level produced a significant decrease in triglyceride and very low-density lipoprotein (VLDL)-cholesterol. Bacnil at TED x 10 produced non-significant increase in triglyceride, VLDL-cholesterol and alkaline phosphate, which suggests that test drug has the potential to damage the liver at a higher dose level on longer administration. But it reverted in recovery study.' Table 4 is applied here symmetrically, against the narrative in both directions. The triglyceride, VLDL-cholesterol and alkaline phosphatase increases at TED x 10 carry no '@' marker (alkaline phosphatase 228.50 +/- 31.10 IU/L control versus 258.11 +/- 21.53 IU/L at TED x 10) and are therefore non-significant, as the authors themselves say. But the decreases at TED that the same sentence calls significant carry no '@' marker either: the triglyceride row reads 135.60 +/- 12.97 control, 97.10 +/- 9.84 at TED, 129.20 +/- 12.51 at TED x 5, 177.89 +/- 29.55 at TED x 10, 140.70 +/- 20.53 at TED x 10 recovery, with no marker in any column, and the VLDL-cholesterol row reads 27.10 +/- 2.54, 19.40 +/- 1.96, 25.80 +/- 2.51, 35.89 +/- 5.96, 28.10 +/- 4.14, again with no marker. The ONLY '@' in the whole of Table 4 is on serum calcium at TED x 10 (10.17 +/- 0.32 mg/dL control versus 9.41 +/- 0.17 mg/dL, P < 0.05) and at TED x 10 recovery (9.46 +/- 0.07 mg/dL, P < 0.05), which the authors record as 'again decreased after discontinuation of drug in recovery study' and read as showing that the 'test drug has a role on calcium turnover in the body'. The authors also state of Table 4 as a whole that 'almost all serum biochemical parameters were within the normal range hence, cannot be categorized as pathological changes'. HAEMATOLOGY, verbatim: 'test drug TED x 10R dose level produced a significant decrease in neutrophil while, a significant increase in monocyte and lymphocyte in comparison to the control group'. Table 5 supports two of those three: neutrophils 8.90 +/- 1.99% at TED x 10 recovery versus control 24.60 +/- 3.83%, marked '@'; lymphocytes 86.20 +/- 1.98% versus control 71.10 +/- 4.06%, marked '@'; but the monocyte row carries no marker in any column (control 2.00 +/- 0.14; TED x 10 recovery 2.60 +/- 0.30). The authors note these changes were within the normal range and conclude that the drug 'does not affect both cellular and noncellular elements of the blood to a significant extent'. AUTHORS' CONCLUSIONS, retained alongside the findings and not in place of them, and to be read against the manufacturer funding disclosed above: 'Repeated dose 28-day oral toxicity revealed that test formulation did not produce any significant change in serum biochemical, hematological, and histopathological parameters at therapeutic dose level'; 'Mild-to-moderate pathological changes were observed in the various serum biochemical and cytoarchitecture of the liver, heart, kidney, and stomach at a dose of 10 TEDs; however, the same was reversed after discontinuation in the recovery test'; and 'Bacnil at 196.2 mg/kg/day is safe at the therapeutic dose level in albino rats.' LIMITATIONS AND MONITORING. The paper contains no separately headed limitations section and states no liver-function monitoring protocol, so none is invented here; it does, however, carry its own hepatic warning, quoted verbatim above, that the test drug 'has the potential to damage the liver at a higher dose level on longer administration'. The study also did not assay the capsule or its ingredients for lead, mercury, arsenic or cadmium, and did not test reproductive, developmental or genotoxic endpoints.Panigrahi B, Sharma S, Sitapara B, De S, Nariya M. Safety profile of Ayurvedic poly-herbomineral formulation - Bacnil capsule in albino rats. Ayu. 2019;40(3):185-191. Nine-ingredient aconite-containing formulation; not a single-ingredient study of Varatika Bhasma. Financially supported by Zoetic Ayurvedic Pvt. Ltd., the manufacturer of the test article; authors declare no conflicts of interest.
• Dose-dependent hepatic, renal, pulmonary and splenic histopathology in mice given fibrous protein extracted from the RAW cowry shell (Cypraea moneta) by intraperitoneal injection; the extracted fibrous protein was also immunogenic in rabbits (single intraperitoneal dose in mice at 10, 100 and 1000 mg/kg body weight, six mice per group, 15-day experimental period; no mortality; no appreciable liver change at 10 mg/kg, damage at higher doses; renal damage described at doses above 100 mg/kg) — SOURCE MATERIAL, NOT THIS PREPARATION, AND NOT THE ORAL ROUTE. Togun et al. worked on cowry shells bought from a local market in Ile-Ife, Nigeria, washed, sun-dried and pulverised. They extracted protein with citrate buffer (pH 2.65) and with phosphate-buffered saline, resolved the citrate-buffer extract into two fibrous proteins CSP1 (91 kDa) and CSP2 (33 kDa), and injected the citrate-buffer protein intraperitoneally into mice. This is raw shell material and an extracted protein fraction given by injection. It is NOT the shodhana-processed, calcined article, it is NOT the oral route, and nothing in it can be transferred to Varatika Bhasma as either harm or reassurance; it is reported because it is the only permitted-source toxicology on the species this preparation is made from, and because dropping it would drop a documented hazard. FINDINGS, verbatim. 'Histopathological examinations revealed a dose-dependent damaging effect of the shell proteins on liver, kidney, lung and spleen tissues of the treated mice.' Liver: 'Examination of the liver sections showed that cowry shell protein had a dose dependent hepatotoxicity effect in mice. At the least dose of 10mg/kg body weight there was no appreciable changes in the liver architecture, but at higher dosage there were damages to the liver', with 'Vacuolation and degenerative ballooning of the hepatocytes, distorted and irregular sinusoids as well as dilatation of the bile canaliculi'. Kidney: 'The kidney morphology revealed a dose-dependent renal damage marked by necrosis and fatty accumulations in the glomerulus of the kidney of mice treated with higher doses of CSP (>100 mg/kg body weight)'. Lung: 'A dose-dependent reduction in the respiratory portion of the lungs marked by different degrees of alveolar wall thickening and air space cellularity'. Spleen: 'Splenic morphology of treated mice showed reactive splenic follicles with increased lymphopoiesis.' Immunogenicity: 'There was no visible precipitin line observed when PBS-extract of cowry shell was reacted with its corresponding antiserum in Ouchterlony agarose gels. However, citrate buffer crude extracts of cowry shells formed clear precipitin lines on reaction with the corresponding antiserum in Ouchterlony plates, and also formed clear precipitin lines in immunoelecrophoresis experiments', from which the authors conclude 'that the fibrous proteins were immunogenic'. THE STUDY'S OWN NEGATIVES AND CAVEATS, carried with the positives. 'There was no mortality recorded from daily observations of all treated and control mice throughout the experimental period.' Body weight, packed cell volume and white blood cell counts showed no significant treatment differences except that 'the mean body weight of group B mice was significantly higher after treatment than before (p<0.05)', which the authors themselves call 'for no apparent reasons'. Damage occurred 'without concurrent physical manifestations of ailment in the mice'. The globular (PBS-extracted) protein fraction 'did not show any evidence of immune activation or toxicity'. The authors also report a contrasting study they did not perform: 'These finding were in agreement with some aspects of the report of Singh et al. (2010) in their toxicity study of oral administration of conch shell (Terbinella pyrum), cowry shell (Cypraea moneta), pearl oyster shell (Pinctada margaritifera), coral root (Tubipora musica), and coral stem (Corallium rubrum) in mice... They did not find any sign of haemopoetic, hepatic or renal toxicity in the control and drug-treated rats. In addition, they did not observe any gross pathological lesion in the liver, stomach and kidney. Our study also did not find any haemopoietic toxicity but showed hepatic, renal, pulmonary and splenic toxicity'. That Singh et al. report is an ORAL study and is described here only as Togun et al. describe it; it is not indexed in PubMed (db=pubmed, term 'Terbinella pyrum toxicity': Count 0) and is not independently cited by this record. The paper carries no separately headed limitations section, states no monitoring protocol, tests no reproductive, developmental or genotoxic endpoint, and performs no elemental assay for lead, mercury, arsenic or cadmium. It gives no evidence as to whether calcination destroys or retains the proteins it identifies; its own recommendation is prospective: 'It is suggested that further studies on the development of biomaterials from cowry shells should include methods for removing or deactivating the protein components.'Togun RA, Balogun RO, Adeyemi DO, et al. Isolation, characterization and immunochemical studies on fibrous proteins from cowry shell (Cypraea moneta, Linnaeus). Afr J Tradit Complement Altern Med. 2016;14(1):110-122. Study of RAW, uncalcined cowry shell and its extracted protein fractions, administered intraperitoneally to mice; not a study of Varatika Bhasma and not the oral route.
• No safety or analytical result of any kind is reported in the only single-ingredient publication located (not reported) — Bhatt's one-page conference abstract in Ancient Science of Life describes an aspirin-induced gastric-lesion model in 'Winstar strain albino rats of either sex' (the abstract's own spelling), 3 groups of 6 rats, dosing for 6 days before lesion induction on day 7. The abstract states of the test article only that 'Varatika bhasma was prepared by shodhana with kanji, bhaavana with kumari swarasa and subjecting to gajaputa. Further it was analyzed and used for experimental study.' It therefore says an analysis was performed and reports no result from it. The supportable statement is the narrow one: the abstract reports no analytical, toxicological, biochemical, haematological, elemental or adverse-event RESULT of any kind, and records no mortality and no tolerability observation. It is NOT stated here that no elemental assay was performed, because the abstract's own sentence will not support that negative. No finding of safety, of freedom from organ toxicity, or of freedom from genotoxic potential may be drawn from it in either direction. Its efficacy content, including its comparator, is deliberately not reproduced in this record. The only numeral it gives for the bhasma appears inside a comparison line paired with a human sucralfate regimen, with no stated recipient, no stated route and no per-kilogram basis, which is why no dose field is carried anywhere in this record.Bhatt P. OA02.09. Evaluation of varatika bhasma for its ulcer protective effect on albino rats. Ancient Science of Life. 2013;32(Suppl 2):S15. One-page conference abstract; efficacy model only, and it reports no analytical, toxicological, biochemical, haematological or adverse-event result of any kind. Title cited verbatim for citation integrity; its therapeutic content is not carried by this record and implies no indication for this preparation.
• Elemental calcium load per dose, hypercalcaemia risk and calcium-carbonate drug-absorption interactions are untested for this preparation (not reported) — Pal et al. state that Varatika is 'Chemically ... carbonate of calcium', but no permitted source reports the elemental calcium content of a marketed dose of Varatika Bhasma, its bioavailability, any hypercalcaemia or milk-alkali observation, or any interaction study with drugs whose absorption is altered by calcium carbonate or by gastric pH. This is a recorded absence of data, not a negative finding, and must not be read as evidence that no such effect occurs. The one calcium-related signal in the located literature is class-level and is in a nine-ingredient aconite-containing formulation, not this preparation: Panigrahi et al. record a significant DECREASE in serum calcium at TED x 10 which persisted in the recovery group, and read it as showing that the 'test drug has a role on calcium turnover in the body'. No calcium-supplement interaction figures were imported from elsewhere; unverifiable content is not cited.Pal D, Sahu CK, Haldar A. Bhasma: The ancient Indian nanomedicine. J Adv Pharm Technol Res. 2014;5(1):4-12. Descriptive and pharmacognostic review; identity and physico-chemical description only, no assay for lead, mercury, arsenic or cadmium.Panigrahi B, Sharma S, Sitapara B, De S, Nariya M. Safety profile of Ayurvedic poly-herbomineral formulation - Bacnil capsule in albino rats. Ayu. 2019;40(3):185-191. Nine-ingredient aconite-containing formulation; not a single-ingredient study of Varatika Bhasma. Financially supported by Zoetic Ayurvedic Pvt. Ltd., the manufacturer of the test article; authors declare no conflicts of interest.

Every statement above was checked by four independent reviewers, each looking for a different kind of error, and published only if the source could be confirmed to say it. How safety data is verified.